Spironolactone in regimens for pseudointractable edema of heart failure.
D000328:Adult; D000368:Aged; D001022:Aortic Valve Insufficiency / Q000150:complications; D001161:Arteriosclerosis / Q000150:complications; D001281:Atrial Fibrillation / Q000150:complications; D001539:Bendroflumethiazide / Q000627:therapeutic use; D002037:Bundle-Branch Block / Q000150:complications; D006332:Cardiomegaly / Q000150:complications; D002740:Chlorothiazide / Q000627:therapeutic use; D048909:Diabetes Complications; D003928:Diabetic Nephropathies / Q000150:complications; D004231:Diuresis / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006857:Hydroflumethiazide / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000150:complications; D008946:Mitral Valve Stenosis / Q000150:complications; D009941:Organomercury Compounds / Q000627:therapeutic use; D011660:Pulmonary Heart Disease / Q000150:complications; D012213:Rheumatic Fever / Q000150:complications; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use*; D014237:Trichlormethiazide / Q000627:therapeutic use
D009941:Organomercury Compounds; D013148:Spironolactone; D006857:Hydroflumethiazide; D001539:Bendroflumethiazide; D002740:Chlorothiazide; D014237:Trichlormethiazide